Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leiner first quarter sales rise 33.2% to $94.1 mil.; recapitalization results in loss.

This article was originally published in The Tan Sheet

Executive Summary

LEINER SALES RISE 33.2% TO $94.1 MIL. IN FIRST QUARTER ended June 30, Leiner Health Products announced Sept. 2. Sales for the quarter were boosted by the recently acquired Vita Health company and higher revenues for both vitamins and OTC drugs. Operating income, excluding expenses related to the company's recent recapitalization, increased 76.8% to $4.2 mil. However, as a result of the recapitalization expenses, the company recorded an operating loss of $16.4 mil. for the quarter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel